Expert Rev Hematol 2017 Jun 6

Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: Focusing on TKI discontinuation due to adverse events - is better always good?

Eskazan AE1, Ozmen D1.
Adverse event; bosutinib; chronic myeloid leukemia; dasatinib; first-line; imatinib; nilotinib; ponatinib; response; tyrosine kinase inhibitor
utinib; chronic myeloid leukemia; dasatinib; first-line; imatinib; nilotinib; ponatinib; response; tyrosine kinase inhibitor